BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
Portfolio Pulse from
BridgeBio Pharma's Attruby has received FDA approval, positioning it as a competitor to Pfizer's Vyndaqel in the ATTR-CM market. Attruby shows a 42% reduction in heart failure risk and 90% TTR stabilization. BridgeBio is set to receive $500 million in milestone payments, with potential for an additional $105 million from EU and Japan approvals.
January 15, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma's Attruby has been approved by the FDA, enhancing its competitive position against Pfizer's Vyndaqel in the ATTR-CM market. The approval triggers $500 million in milestone payments, with potential for more from EU and Japan.
The FDA approval of Attruby significantly boosts BridgeBio's market position and financial outlook, with substantial milestone payments and potential for further international approvals.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's Vyndaqel faces new competition from BridgeBio's Attruby following its FDA approval. Attruby's superior profile in some cases may impact Vyndaqel's market share.
Attruby's approval introduces a strong competitor to Pfizer's Vyndaqel, potentially affecting its market share due to Attruby's promising clinical profile.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70